A5080431093- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Tracheal and airway disorders
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Medical Imaging and Pathology Studies
- Cancer-related molecular mechanisms research
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Heat shock proteins research
- Cancer Diagnosis and Treatment
- ATP Synthase and ATPases Research
- Metastasis and carcinoma case studies
- Congenital Diaphragmatic Hernia Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Mitochondrial Function and Pathology
- Epigenetics and DNA Methylation
- Cardiac tumors and thrombi
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- Glioma Diagnosis and Treatment
Sichuan University
2016-2025
West China Hospital of Sichuan University
2016-2025
State Key Laboratory of Biotherapy
2012-2024
Barro Colorado Island
2024
Swiss HIV Cohort Study
2024
South China Institute of Collaborative Innovation
2016-2023
English Heritage
2023
Charlottesville Medical Research
2023
New York Proton Center
2023
Digital Scholar (United States)
2023
A nomogram is a useful and convenient tool for individualized cancer prognoses. We sought to develop clinical predicting survival of patients with resected non-small-cell lung (NSCLC).On the basis data from multi-institutional registry 6,111 NSCLC in China, we identified integrated significant prognostic factors build nomogram. The model was subjected bootstrap internal validation external separate cohort 2,148 International Association Study Lung Cancer (IASLC) database. predictive accuracy...
Purpose We investigated the correlation between number of examined lymph nodes (ELNs) and correct staging long-term survival in non–small-cell lung cancer (NSCLC) by using large databases determined minimal threshold for ELN count. Methods Data from a Chinese multi-institutional registry US SEER database on stage I to IIIA resected NSCLC (2001 2008) were analyzed relationship count migration overall (OS) multivariable models. The series mean positive LNs, odds ratios (ORs), hazard (HRs)...
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor ( EGFR) mutation-positive resected stage II-IIIA (N1-N2) non–small-cell lung cancer (NSCLC). Here, we report the final overall (OS) results. METHODS From September 2011 to April 2014, 222 from 27 sites were...
Abstract Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a biomarker for early detection of molecular residual disease (MRD) and prediction postoperative relapse in resected non–small cell lung cancer (NSCLC). Experimental Design: Based on our prospective, multicenter cohort dynamic monitoring ctDNA surgery patients (LUNGCA), we enrolled 950 plasma samples obtained at three time points (before surgery, 3 days 1 month after surgery) 330 stage I–III NSCLC...
Importance Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition chemotherapy remains unknown. Objective To determine whether toripalimab in platinum-based will improve event-free survival major pathological response stage II or III resectable NSCLC compared alone. Design, Setting, Participants This randomized trial enrolled (without EGFR ALK...
Diagnosing lung cancer from indeterminate pulmonary nodules (IPLs) remains challenging. In this multi-institutional study involving 2032 participants with IPLs, we integrate the clinical, radiomic circulating cell-free DNA fragmentomic features in 5-methylcytosine (5mC)-enriched regions to establish a multiomics model (clinic-RadmC) for predicting malignancy risk of IPLs. The clinic-RadmC yields an area-under-the-curve (AUC) 0.923 on external test set, outperforming single-omics models, and...
Abstract Background Tumor microenvironment is composed of tumor cells, fibroblasts, endothelial and infiltrating immune cells. Tumor-associated cells may inhibit or promote growth progression. This study was conducted to determine whether the number microlocalization macrophages, mature dendritic cytotoxic T in non-small cell lung cancer are associated with patient's survival time. Methods Ninety-nine patients (NSCLC) were included this retrospective study. Paraffin-embedded NSCLC specimens...
MicroRNAs (miRNAs) are small 19- to 24-nt noncoding RNAs that have the capacity regulate fundamental biological processes essential for cancer initiation and progression. In cancer, miRNAs may function as oncogenes or tumor suppressors. Here, we conducted global profiling in a cohort of stage 1 nonsmall cell lung cancers ( n = 81) determined miR-486 was most down-regulated miRNA tumors compared with adjacent uninvolved tissues, suggesting loss be important development. We report directly...
Oncogenic fusion gene Echinoderm Microtubule-associated protein-Like 4-Anaplastic Lymphoma Kinase (EML4-ALK) contributes to tumorigenesis of a subset non-small cell lung cancer (NSCLC). Recently, we demonstrated that F-circEA-4a, tumor-promoting circular RNA (circRNA) generated from the back-splicing EML4-ALK variant 3b (v3b), is novel liquid biopsy biomarker for NSCLC. However, circRNAs produced and their roles in NSCLC are not well-characterized. Here, identify another EML4-ALK-v3b-derived...
The characteristics of cancer cells, such as invasiveness, are affected by the tumor microenvironment. Studies have shown that interleukin (IL)-6 and necrosis factor (TNF)-α regulate proliferation lung cancer. However, few studies focused on effects IL-6 TNF-α metastasis present study was designed to investigate whether can promote non-small cell (NSCLC). Sixty-five matched adjacent tissue samples from patients with NSCLC corresponding serum were collected. Thirty healthy subjects selected...
Abstract Long noncoding RNAs (lncRNA) are emerging as a novel class of regulators in gene expression associated with tumorigenesis. However, the role lncRNAs papillary thyroid carcinoma (PTC) is poorly understood. Here, we conducted global lncRNA profiling and identified AB074169 (lncAB) significantly downregulated PTC. Decreased lncAB PTC was caused by CpG hypermethylation within its promoter. Functional studies showed that overexpression led to cell-cycle arrest tumor growth inhibition...
It is important to develop a surgical technique reduce dissemination of tumor cells into the blood during surgery.To compare outcomes different sequences vessel ligation surgery on and survival in patients with non-small cell lung cancer.This multicenter, randomized clinical trial was conducted from December 2016 March 2018 cancer who received thoracoscopic lobectomy West China Hospital, Daping Sichuan Cancer Hospital. To further 2 procedures, we reviewed Western Lung database (2005-2017)...
Radiotherapy remains one of the major treatments for non-small cell lung cancer (NSCLC) patients; whereas intrinsic or acquired radioresistance limits its efficacy. Nevertheless, most studies so far have only focused on resistance. The exact mechanisms in NSCLC are still unclear. A few suggested that epithelial-mesenchymal transition (EMT) is associated with NSCLC. However, little known about whether abnormal expression specific microRNAs induces both EMT and radioresistance. We previously...
Abstract The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival resected EGFR -mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising necessity for further biomarker assessment. In this work, by comprehensive genomic profiling 171 tumor tissues from trial, five predictive biomarkers are identified ( TP53 exon4/5...